R. Storb

Allen R. Chen, S. Piantadosi, C. Huff, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation.

K. Sullivan, M. Benyunes, H. Deeg, 1995, International journal of radiation oncology, biology, physics.

Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts.

M. Pepe, F. Appelbaum, G. Sale, 1989, Blood.

Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin.

R. Storb, M. Cheever, E. Thomas, 1979, The New England journal of medicine.

Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation

H. Deeg, R. Storb, W. Leisenring, 1998, Bone Marrow Transplantation.

Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita

R. Storb, R. Seger, T. Güngör, 2003, Bone Marrow Transplantation.

Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.

R. Storb, F. Appelbaum, T. Gooley, 1996, Blood.

Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man.

R. Storb, E. Jones, K. Atkinson, 1978, Journal of immunology.

Thalidomide for treatment of patients with chronic graft-versus-host disease.

H. Deeg, R. Storb, W. Leisenring, 2000, Blood.

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

R. Storb, J. Hansen, P. Beatty, 1990, Human immunology.

Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

H. Deeg, R. Storb, F. Appelbaum, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

J. Fay, R. Storb, S. Davies, 2000, Blood.

Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance.

R. Storb, P. Weiden, E. Thomas, 1976, Journal of immunology.

Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention.

M. Pepe, R. Storb, G. Longton, 1994, Blood.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2008 .

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.

B. Storer, M. Boeckh, M. Flowers, 2009, Blood.

Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?

H. Deeg, M. Pepe, K. Sullivan, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second marrow infusion for poor graft function after allogeneic marrow transplantation.

K. Sullivan, R. Storb, G. Bolger, 1986, Bone marrow transplantation.

Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities

H. Deeg, K. Sullivan, R. Storb, 2000, Bone Marrow Transplantation.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

J. Fay, R. Storb, S. Davies, 2000, Blood.

The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells.

H. Deeg, V. Farewell, R. Storb, 2008, Tissue antigens.

Paroxysmal Nocturnal Haemoglobinuria and Refractory Marrow Failure Treated by Marrow Transplantation

P. Neiman, R. Storb, E. Thomas, 1973, British journal of haematology.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

H. Deeg, M. Sorror, M. Maris, 2014, Blood.

FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.

J. Fay, H. Deeg, K. Sullivan, 1996, Blood.

Allogeneic marrow transplantation.

K. Sullivan, R. Storb, R. Storb, 1984, Cancer investigation.

Allogeneic marrow grafting for treatment of aplastic anemia: a follow-up on long-term survivors.

P. Neiman, R. Storb, E. Thomas, 1976, Blood.

The effect of prior transfusion on marrow grafts between histocompatible canine siblings.

R. Storb, E. Thomas, R. Rudolph, 1970, Journal of immunology.

Non-myeloablative hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century.

R. Storb, B. Sandmaier, D. Maloney, 2000, Transplantation proceedings.

Marrow transplantation in the treatment of acute leukemia.

P. Neiman, R. Storb, E. Thomas, 1978, Advances in cancer research.

Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants.

K. Sullivan, R. Storb, J. Meyers, 1984, The American journal of medicine.

Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.

R. Storb, F. Appelbaum, W. Bensinger, 1996, Bone marrow transplantation.

Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL.

R. Storb, R. Nash, R. Storb, 1996, Current opinion in immunology.

DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment.

H. Deeg, B. Sandmaier, C. Yu, 1995, Blood.

Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells.

H. Deeg, R. Storb, S. Slichter, 1979, Blood.

Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis.

R. Storb, B. Camitta, E. Thomas, 1982 .

Secondary failure of platelet recovery after hematopoietic stem cell transplantation.

K. Sullivan, R. Storb, T. Gooley, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.

K. Sullivan, K. Kopecky, J. Meyers, 1990, The New England journal of medicine.

Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial.

H. Deeg, F. Appelbaum, R. Storb, 1995, International journal of radiation oncology, biology, physics.

Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation.

K. Sullivan, F. Appelbaum, N. Flournoy, 1987, Annals of internal medicine.

MARROW TRANSPLANTATION FOR THALASSAEMIA

J. Sanders, R. Storb, E. Thomas, 1982, The Lancet.

Proliferative and differentiative responses of B cells from human marrow graft recipients to T cell-derived factors.

R. Storb, K. Matsue, L. Lum, 1987, Blood.

E. Petersdorf, A. Balduzzi, F. Appelbaum, 1995, Blood.

Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

R. Storb, F. Appelbaum, G. Schoch, 1990 .

High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.

K. Sullivan, R. Storb, F. Appelbaum, 1989, Bone marrow transplantation.

Allogeneic marrow transplantation for acute lymphoblastic leukemia in remission using fractionated total body irradiation.

K. Sullivan, R. Storb, G. Sale, 1982, Leukemia research.

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission.

R. Storb, F. Appelbaum, K. Kopecky, 1987, Bone marrow transplantation.

High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.

R. Storb, F. Appelbaum, S. Riddell, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation.

J. D. Thompson, J. Thompson, R. Storb, 2000, Blood.

Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens.

H. Deeg, K. Sullivan, R. Storb, 1987, Experimental hematology.

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.

H. Deeg, R. Storb, B. Sandmaier, 2019, Blood.

Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.

J. Nemunaitis, R. Storb, C. Higano, 1991, Blood.

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

B. Clurman, H. Deeg, R. Storb, 2007, Blood.

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia.

B. Storer, A. Woolfrey, M. Flowers, 2011, Blood.

Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.

R. Storb, B. Sandmaier, W. Leisenring, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis).

R. Storb, B. Sandmaier, W. Leisenring, 1998, Blood.

Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter]

H. Deeg, M. Pepe, R. Storb, 1991 .

Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.

K. Sullivan, R. Storb, F. Appelbaum, 1998, Blood.

Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts.

H. Deeg, R. Storb, B. Sandmaier, 1998, Blood.